Liqun Qu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Liqun Qu has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Betty Yuen Kwan Law
State Key Laboratory of Quality Research in Chinese Medicine, Faculty of Chinese Medicine, Macau University of Science and Technology, Avenida Wai Long, Taipa, Macau, 999078, China
3 shared publications - Vincent Kam Wai Wong
Macau University of Science and Technology
3 shared publications - Jerome P. L. Ng
Dr. Neher’s Biophysics Laboratory for Innovative Drug Discovery, State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Macau 999078, China
2 shared publications - Mengyu Wang
Faculty of Chinese Medicine, Macau University of Science and Technology, Macau, China
2 shared publications - Xianjun Fu
Key Laboratory of Marine Traditional Chinese Medicine in Shandong Universities, Research Institute for Marine Traditional Chinese Medicine (Qingdao Academy of Chinese Medical Sciences), The SATCM’s Key Unit of Discovering and Developing New Marine TCM Drugs, Shandong University of Traditional Chinese Medicine, China
2 shared publications - Anguo Wu
Sichuan Key Medical Laboratory of New Drug Discovery and Druggability Evaluation Key Laboratory of Medical Electrophysiology of Ministry of Education, School of Pharmacy Southwest Medical University Luzhou China
1 shared publication
Latest Publications
- 2 April 2026
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (9) , 1-24
Medicinal seahorses (Hippocampus spp.) for Alzheimer’s disease within species conservation framework: an integrated review of ethnopharmacology, bioactivity, bibliometrics, and network pharmacology
Seahorses (Hippocampus spp.) have been used in traditional Chinese medicine for centuries and are now regarded as underexplored but promising marine resources for modern drug discovery. This review reassesses medicinal seahorses as a potential marine resource for identifying multi-target candidates relevant to Alzheimer’s disease (AD) by integrating taxonomy and distribution, conservation, and aquaculture status, ethnomedicinal use, chemical composition, and pharmacology, as well as bibliometric and network-pharmacology analyses. Using published surveys and global databases, we collated records indicating 16 Hippocampus species in Chinese waters and identify five pharmacopeial taxa whose dependence on fragile coastal habitats contrasts with the recent expansion of captive-breeding, tank and pond-based culture, suggesting that regulated aquaculture can supply traceable raw material and alleviate pressure on wild populations. Bibliometric mapping of Web of Science records (1979–2024) shows a shift from aquaculture and conservation towards antioxidant, anti-inflammatory, neuroprotective, and AD-related research. Across the five medicinal species, 329 reported constituents reflect substantial chemical diversity that may contribute to antioxidant, anti-inflammatory, neuroprotective, endocrine and immunomodulatory activities with potential relevance to AD-related pathophysiology. Network-pharmacology analysis links 276 structurally defined compounds to an AD-associated gene module, highlighting a core module centered on APP, JUN and PPARγ as putative mechanistic nodes. This article is based solely on published data and involves no new field collection or experimentation on wild seahorses. We propose that future work should rely on species-verified, aquaculture-derived material, rigorous chemical characterization, and quality control, AD-focused mechanistic and pharmacokinetic studies, and synthetic or biotechnological production of key constituents to support the ethically and ecologically responsible exploration of Hippocampus-based candidates relevant to AD.
- 2 April 2026
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (9) , 1-24
Medicinal seahorses (Hippocampus spp.) for Alzheimer’s disease within species conservation framework: an integrated review of ethnopharmacology, bioactivity, bibliometrics, and network pharmacology
Seahorses (Hippocampus spp.) have been used in traditional Chinese medicine for centuries and are now regarded as underexplored but promising marine resources for modern drug discovery. This review reassesses medicinal seahorses as a potential marine resource for identifying multi-target candidates relevant to Alzheimer’s disease (AD) by integrating taxonomy and distribution, conservation, and aquaculture status, ethnomedicinal use, chemical composition, and pharmacology, as well as bibliometric and network-pharmacology analyses. Using published surveys and global databases, we collated records indicating 16 Hippocampus species in Chinese waters and identify five pharmacopeial taxa whose dependence on fragile coastal habitats contrasts with the recent expansion of captive-breeding, tank and pond-based culture, suggesting that regulated aquaculture can supply traceable raw material and alleviate pressure on wild populations. Bibliometric mapping of Web of Science records (1979–2024) shows a shift from aquaculture and conservation towards antioxidant, anti-inflammatory, neuroprotective, and AD-related research. Across the five medicinal species, 329 reported constituents reflect substantial chemical diversity that may contribute to antioxidant, anti-inflammatory, neuroprotective, endocrine and immunomodulatory activities with potential relevance to AD-related pathophysiology. Network-pharmacology analysis links 276 structurally defined compounds to an AD-associated gene module, highlighting a core module centered on APP, JUN and PPARγ as putative mechanistic nodes. This article is based solely on published data and involves no new field collection or experimentation on wild seahorses. We propose that future work should rely on species-verified, aquaculture-derived material, rigorous chemical characterization, and quality control, AD-focused mechanistic and pharmacokinetic studies, and synthetic or biotechnological production of key constituents to support the ethically and ecologically responsible exploration of Hippocampus-based candidates relevant to AD.
- Open Access
- 9 September 2024
- Published by MDPI AG in Metabolites
- Vol. 14 (9) , 490
Natural Products and Derivatives Targeting Metabolic Reprogramming in Colorectal Cancer: A Comprehensive Review
Metabolic reprogramming is a critical pathogenesis of colorectal cancer (CRC), referring to metabolic disorders that cancer cells make in response to the stimulating pressure. Metabolic reprogramming induces changes in genetic material and promotes CRC progression and has been proven to be an efficient target of CRC. As natural products have garnered interest due to notable pharmacological effects and potential in counteracting chemoresistance, an increasing body of research is delving into the impact of these natural products on the metabolic reprogramming associated with CRC. In this review, we collected published data from the Web of Science and PubMed, covering the period from January 1980 to October 2023. This article focuses on five central facets of metabolic alterations in cancer cells, glucose metabolism, mitochondrial oxidative phosphorylation (OXPHOS), amino acid metabolism, fatty acid synthesis, and nucleotide metabolism, to provide an overview of recent advancements in natural product interventions targeting metabolic reprogramming in CRC. Our analysis underscores the potential of natural products in disrupting the metabolic pathways of CRC, suggesting promising therapeutic targets for CRC and expanding treatment options for metabolic-associated ailments.
- 9 September 2024
- Published by MDPI AG in Metabolites
- Vol. 14 (9) , 490
Open AccessNatural Products and Derivatives Targeting Metabolic Reprogramming in Colorectal Cancer: A Comprehensive Review
Metabolic reprogramming is a critical pathogenesis of colorectal cancer (CRC), referring to metabolic disorders that cancer cells make in response to the stimulating pressure. Metabolic reprogramming induces changes in genetic material and promotes CRC progression and has been proven to be an efficient target of CRC. As natural products have garnered interest due to notable pharmacological effects and potential in counteracting chemoresistance, an increasing body of research is delving into the impact of these natural products on the metabolic reprogramming associated with CRC. In this review, we collected published data from the Web of Science and PubMed, covering the period from January 1980 to October 2023. This article focuses on five central facets of metabolic alterations in cancer cells, glucose metabolism, mitochondrial oxidative phosphorylation (OXPHOS), amino acid metabolism, fatty acid synthesis, and nucleotide metabolism, to provide an overview of recent advancements in natural product interventions targeting metabolic reprogramming in CRC. Our analysis underscores the potential of natural products in disrupting the metabolic pathways of CRC, suggesting promising therapeutic targets for CRC and expanding treatment options for metabolic-associated ailments.
- Open Access
- 14 August 2023
- Published by Elsevier in Pharmacological Research
- Vol. 196, 106874
Tricin promoted ATG-7 dependent autophagic degradation of α-synuclein and dopamine release for improving cognitive and motor deficits in Parkinson's disease
- 14 August 2023
- Published by Elsevier in Pharmacological Research
- Vol. 196, 106874
Open AccessTricin promoted ATG-7 dependent autophagic degradation of α-synuclein and dopamine release for improving cognitive and motor deficits in Parkinson's disease